Press release Biocartis Group NV: New Idylla™ EGFR Study Shows
Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
PRESS RELEASE: 8 November 2022, 07:00 CET
New Idylla™
EGFR Study Shows Reduction
of Time-to-Treatment by 48% for Lung Cancer
PatientsIdylla™ EGFR Mutation Test (CE-IVD) leading to
time-to-treatment on average 16.8 days faster than Next Generation
Sequencing (NGS) for EGFR positive patients, as such showing
Idylla™’s potential to improve strategic treatment decisions of
patients with advanced non-small cell lung cancer
Mechelen, Belgium,
8 November 2022
– Biocartis Group NV (the ‘Company’ or
‘Biocartis’), an innovative molecular diagnostics company (Euronext
Brussels: BCART), today announces the recent publication of a new,
large prospective study1 demonstrating that the Idylla™ EGFR
Mutation Test (CE-IVD2) leads to the significant reduction of the
time-to-treatment by 48% or on average 16.8 days faster than NGS
testing for EGFR positive patients. This shows Idylla™’s potential
to improve strategic treatment decisions within a multidisciplinary
team for patients with advanced non-small cell lung cancer
(NSCLC).
Herman Verrelst, Chief Executive Officer
of Biocartis, commented: “Tailoring cancer treatments to
individual patients is key, and require molecular diagnostic
testing to help identify the specific biomarkers involved. Recent
studies3 among approximately 1,600 patients show that in many
European countries, less than 50% of the patients undergo biomarker
testing. This is due to, among other reasons, lack of diagnostic
laboratory infrastructure which also hinders a broader uptake of
more complex testing technologies such as NGS. Integrating
decentralized, rapid and easy-to-use Idylla™ testing in routine use
can help broaden access to biomarker testing and as such, improve
patient treatment and outcomes. We are therefore very pleased with
another study showing the significant impact of Idylla™ on
time-to-treatment that is no less than 16.8 days faster than NGS
for EGFR positive patients with advanced NSCLC.”
The study was performed on 238 samples which
were tested both using an NGS panel (Oncopanel) and the Idylla™
EGFR Mutation Test4. The study showed a concordance of 98.7%
between the Idylla™ EGFR Mutation Test and the NGS panel. The lab
turnaround time was faster for the Idylla™ EGFR Mutation Test by an
average of 12.4 days. In the EGFR positive cohort, the Idylla™ EGFR
Mutation Test led to a 48% reduction and on average 16.8 days
faster turnaround time.
Furthermore, the study concludes that the
Idylla™ EGFR Mutation Test could contribute to overall time and
cost savings for patients if testing is implemented in a stepwise
manner, where the Idylla™ EGFR Mutation Test and the PD-L1 IHC
(Immunohistochemistry) test are performed first, and comprehensive
yet more expensive NGS panel testing is only initiated in case of a
negative Idylla™ EGFR Mutation Test. Such first-line use of Idylla™
EGFR Mutation Test is not only more cost-effective, but it also
allows to obtain EGFR test results in the same time frame as the
PD-L1 IHC test results, which is important as EGFR positivity may
be a contra-indication for PD-1/PD-L1 therapy in NSCLC5.
The impact of the rapid Idylla™ EGFR Mutation
Test on turnaround times is in line with previous studies6
published, concluding that Idylla™ testing early on may contribute
to improving strategic treatment decisions in a multidisciplinary
team for patients with NSCLC by the early screening of EGFR
mutations.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com tel
+32 15 631 729
mobile 32 471 53 60 64
About Biocartis
With its revolutionary and proprietary Idylla™
platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™’s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for COVID-19, Flu,
RSV and sepsis. For more information, visit www.biocartis.com
or follow Biocartis on Twitter @Biocartis_ , Facebook or
LinkedIn.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
1 Banyi N, Alex D, Hughesman C, McNeil K, N Ionescu D, Ma C, Yip
S, Melosky B. Improving Time-to-Treatment for Advanced Non-Small
Cell Lung Cancer Patients through Faster Single Gene EGFR Testing
Using the Idylla™ EGFR Testing Platform. Curr Oncol. 2022 Oct
18;29(10):7900-7911. doi: 10.3390/curroncol29100624. PMID:
362909012 The Idylla™ platform is cleared in the US under K163628.
Idylla™ EGFR assay is for Research Use Only in the United States,
not for use in diagnostic procedures. For more information, go to
https://www.biocartis.com/en-US3 Normanno N, Apostolidis K, Wolf A,
Al Dieri R, Deans Z, Fairley J, Maas J, Martinez A, Moch H, Nielsen
S, Pilz T, Rouleau E, Patton S, Williams V. Access and quality of
biomarker testing for precision oncology in Europe. Eur J Cancer.
2022 Oct 1;176:70-77. doi: 10.1016/j.ejca.2022.09.005. Epub ahead
of print. PMID: 361949054 For each patient, the time that the lab
received the sample, the time taken to report the NGS and Idylla™
testing results, the time of first treatment and the final
treatment regimen were taken into account5 J. Mazieres et al.
Immune checkpoint inhibitors for patients with advanced lung cancer
and oncogenic driver alterations: results from the IMMUNOTARGET
registry. Annals of Oncology 20196 Including Petiteau C,
Robinet-Zimmermann G, Riot A, Dorbeau M, Richard N, Blanc-Fournier
C, Bibeau F, Deshayes S, Bergot E, Gervais R, Levallet G.
Contribution of the IdyllaTM System to Improving the
Therapeutic Care of Patients with NSCLC through Early Screening
of EGFR Mutations. Curr Oncol. 2021 Nov
3;28(6):4432-4445. doi: 10.3390/curroncol28060376. PMID: 34898548;
PMCID: PMC8628756; Finall A, Davies G, Jones T,
et al. J Clin Pathol Epub ahead of print. doi:10.1136/
jclinpath-2021-207987
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024